In November, a significant number of American voters opted for Republican candidates, aiming to reduce the size of government.
Yet, it raises the question: why are Republicans adopting socialist pricing models for medications from foreign single-payer healthcare systems?
This was evident when President Trump, with a quick signature, enacted an executive order that connects U.S. drug prices to the manufactured rates set by health systems abroad.
Trump’s order aims to ensure that foreign nations do not implement policies that unfairly burden American patients with excessive costs of global pharmaceutical research, by keeping drug prices artificially low.
However, the approach seems to misfire by disadvantaging American pharmaceutical companies. By enforcing similar low domestic prices that foreign health systems impose, these companies could struggle financially.
This controversial policy is dubbed Most Favored Nation. To those unfamiliar, it might sound like a diplomatic success, but, in reality, it’s a misguided concept.
Health expert Sally Pipes argues that this is essentially price fixing rather than genuine market reform. She suggests that Republicans endorsing this strategy are drifting away from free-market ideals.
In short, the Most Favored Nation policy applies lower drug prices from socialized healthcare systems to the U.S. “Countries like France and the UK don’t negotiate prices—they establish them,” Pipes elaborates, noting the serious consequences for manufacturers who resist.
It’s disheartening to witness Republicans mimic Democrats in policy choices. If people desire price controls, they could just elect Democrats who typically advocate for such measures.
This policy could significantly harm pharmaceutical revenues due to government-imposed low pricing, leading to fewer investments in essential research and development. New medications can cost billions to develop, mostly because 92% of potential drugs fail during trials.
The War on R&D could reduce available treatments at a time when a large number of baby boomers are reaching Medicare age.
Instead of instituting Republican price controls, Trump should leverage trade negotiations to challenge foreign systems that force U.S. companies into selling medications at unsustainably low prices.
Trump ought to shift the financial burden back to foreign entities, making it clear: if they want U.S. drugs, they ought to pay U.S. prices.
Additionally, Republicans could save taxpayer funds by reforming Medicaid without compromising benefits for those in need, like pregnant women or low-income families.
Firstly, ending Medicaid for illegal immigrants could lead to substantial savings, with the Foundation for Government Accountability estimating a potential $282 billion saved over a decade—a majority of voters support this idea.
Secondly, combating Medicaid fraud is critical, as recent reports show billions lost to improper payments, with a significant amount potentially due to corruption.
Lastly, encouraging able-bodied adults without children to contribute through work or training could help improve their situation. This idea garners broad support and could save considerable taxpayer money in the long run.
Ultimately, Republicans need to steer clear of price controls and instead guide Medicaid towards a model that aligns with limited government principles.
